Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l.—making Covis a wholly-owned subsidiary of Azurity. This acquisition reinforces Azurity’s leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale. Azurity’s acquisition of Covis e...